293 related articles for article (PubMed ID: 12469156)
21. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Allevi G; Bolsi G; Aguggini S; Brunelli A; Betri E; Generali D; Scaratti L; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2002 Jun; 8(6):1816-21. PubMed ID: 12060622
[TBL] [Abstract][Full Text] [Related]
22. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneic expression of estrogen receptor between the primary tumor and the corresponding involved lymph nodes in patients with node-positive breast cancer and its implications in patient outcome.
Iguchi C; Nio Y; Itakura M
J Surg Oncol; 2003 Jun; 83(2):85-93. PubMed ID: 12772201
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.
Kim HS; Yom CK; Kim HJ; Lee JW; Sohn JH; Kim JH; Park YL; Ahn SH
Breast Cancer Res Treat; 2010 Jun; 121(3):777-88. PubMed ID: 19806450
[TBL] [Abstract][Full Text] [Related]
25. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
26. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer.
Sjöström J; Blomqvist C; von Boguslawski K; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Wist E; Valvere V; Takayama S; Reed JC; Saksela E
Clin Cancer Res; 2002 Mar; 8(3):811-6. PubMed ID: 11895913
[TBL] [Abstract][Full Text] [Related]
27. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
[TBL] [Abstract][Full Text] [Related]
28. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
[TBL] [Abstract][Full Text] [Related]
29. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T
Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
31. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
32. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
33. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
Borgquist S; Jögi A; Pontén F; Rydén L; Brennan DJ; Jirström K
Breast Cancer Res; 2008; 10(5):R79. PubMed ID: 18808688
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
Chen S; Chen CM; Yu KD; Zhou RJ; Shao ZM
Ann Surg Oncol; 2012 Sep; 19(9):3002-11. PubMed ID: 22437200
[TBL] [Abstract][Full Text] [Related]
36. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
[TBL] [Abstract][Full Text] [Related]
37. Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy.
Prisack HB; Karreman C; Modlich O; Audretsch W; Danae M; Rezai M; Bojar H
Anticancer Res; 2005; 25(6C):4615-21. PubMed ID: 16334152
[TBL] [Abstract][Full Text] [Related]
38. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
39. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
Rudas M; Lehnert M; Huynh A; Jakesz R; Singer C; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Grill R; Stierer M; Gnant MF; Filipits M;
Clin Cancer Res; 2008 Mar; 14(6):1767-74. PubMed ID: 18347178
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
